China Medical Device Commercialization: Crossing the Valley of Death with TRL Assessment & NMPA's EP Checklist
Getting a medical device innovation from a research institution to China's market is one of the most demanding commercialization challenges in any industry. The regulatory requirements are high, the timelines are long, and the gap between a working laboratory prototype and a registrable product is wider than most innovators expect. This article examines the structural reasons why promising innovations stall — the "Valley of Death" — and provides a practical framework for using Technology Readiness Levels (TRL) to assess registration readiness, with a focused look at how NMPA's EP Checklist translates these requirements into a submission structure.
Why Chinese Medical Device Innovations Stall: The Structural Challenges
China's 14th Five-Year Plan for pharmaceutical and medical device industry development identified five persistent structural weaknesses that explain why the innovation pipeline underperforms despite strong R&D investment:
- Weak basic research, crowded hotspot development. Investment concentrates on established high-value targets (oncology markers, cardiovascular stents, AI imaging) producing intense homogeneous competition, while genuinely differentiated innovation from basic science is underfunded.
- Fragmented industrial ecosystem. Large, medium, and small enterprises have not formed the coordinated development ecosystem that would allow small innovators to access manufacturing, clinical, and distribution capabilities efficiently.
- Insufficient rare disease and pediatric device development. Commercial incentives for rare disease and pediatric device development remain weak; industry response to major public health events needs strengthening.
- Quality control gaps in supply chain. Raw materials, key components, and manufacturing process quality control in domestic production often do not meet the standards required for Class III registration.
- Slow export upgrading. Export structure is dominated by low-value products; high-value innovative devices lack the international clinical evidence base to compete globally.
The Valley of Death: Where Innovation Disappears
The "Valley of Death" is the well-documented commercialization gap between applied research (TRL 3–5) and manufacturable product (TRL 7+). In medical devices, this valley is wider and deeper than in most other industries — because crossing it requires not just engineering maturity but also regulatory-grade documentation, clinical evidence, and quality system compliance.
The four ways innovations die in the Valley
- Experiment ≠ product: Research outputs stop at initial proof of concept; stability is unproven; the gap between a lab demonstration and a manufacturable, reliable product is systematically underestimated.
- Scale-up collapse: When moving from bench to production scale, costs spike, manufacturing complexity multiplies, and no reliable engineering pathway exists to maintain performance at volume.
- Technology suspended without real use context: The device is developed without genuine clinical scenario validation — it solves a problem in theory but lacks real hospital workflow integration or clinical champion support.
- Project-dependent survival: Research outputs exist only as long as grant funding continues. When the project ends, so does the device — there is no mechanism to sustain development through commercialization.
From a registration perspective, the Valley of Death maps directly onto the gap between what research institutions produce and what NMPA requires. A laboratory prototype, however impressive, cannot be registered. What NMPA reviews is a product — with defined specifications, validated manufacturing processes, documented design history, and clinical performance data from studies conducted under GCP/GLP conditions.
Technology Readiness Levels (TRL): The Commercialization Map
The TRL framework — originally developed by NASA in the 1970s and later adopted by the US Department of Defense, EU Horizon programs, and China's standardization authorities — provides a 9-level scale for assessing how mature a technology is relative to real-world deployment. China formally adopted TRL methodology through GB/T 22900-2009 (general technology evaluation) and GJB 7688/7689-2012 (defense equipment). Guangdong province was the first to formally apply TRL to medical device innovation in its 2018 high-end device and additive manufacturing special programs; national 12th, 13th, and 14th Five-Year Plan major instrument programs all use TRL for mid-term review and final acceptance.
For medical device registration, the TRL scale maps as follows:
Registration readiness rule of thumb: NMPA registration submissions should not be attempted before TRL 7. Products at TRL 4–5 are still in applied research and lack the manufacturing validation, clinical data, and quality system documentation that technical review requires. Attempting early submission wastes regulatory fees and creates a negative review record without correcting the underlying readiness gap.
The Six Dimensions of Commercialization Success
For institutional innovators and companies bridging the Valley of Death, six critical dimensions determine whether an innovation successfully reaches the registration stage:
- Technology identification: TRL scoring by expert panel; assessment of industrialization potential. The key question: does this technology have the foundation to become a product, or does it require further basic research?
- Maturation support: Bench-scale validation (小试), proof-of-concept prototype (POC). The critical resource question: who provides the scenario, equipment, and technical expertise for the developer to test the device in realistic conditions?
- Scenario implantation: Matching the device to specific clinical workflows and validated hospital partner needs. Is the clinical need real, specific, and quantified — or assumed?
- Investment consensus: Capital entry for early-stage validation costs. Who bears the cost of testing, verification, and clinical feasibility before commercial viability is established?
- Deal structure: Clear licensing, valuation, incubation pathway, and risk/reward allocation between the innovator, manufacturer, and investor.
- Capability accumulation: Capturing data, models, and decision experience from the development process to build platform-level capabilities that outlast any single product.
NMPA's Safety & Performance Framework: What the Review Actually Evaluates
NMPA technical review is fundamentally a risk-benefit assessment. The regulatory definition of safety under GB/T 42062 (China's adoption of ISO 14971) is "freedom from unacceptable risk." The technical review conclusion is whether the device's benefits (efficacy in achieving its intended use) outweigh its risks (harm potential), yielding a net benefit-risk balance that justifies market authorization.
This assessment is structured around two documents that all Class II and III device submissions must include:
- Basic Principles of Safety and Performance for Medical Devices (医疗器械安全和性能基本原则) — China's equivalent of IMDRF 2018 Essential Principles, covering 13 chapters applicable to all devices, plus device-specific requirements for implantables, energy-delivering devices, drug-device combinations, and IVDs.
- EP Checklist (符合性技术指南) — the conformity demonstration matrix that links each applicable requirement to the conformity method and objective evidence provided in the dossier.
The EP Checklist: From Requirement to Evidence
The EP Checklist is the structural backbone of NMPA technical review. For each of the 13 Basic Principles chapters, the manufacturer must state: (1) whether the requirement applies to the product; (2) what method was used to demonstrate conformity; and (3) what objective evidence is provided — distinguishing between evidence included in the registration dossier and evidence held on file at the manufacturer (verifiable during on-site review).
| EP Chapter | Coverage |
|---|---|
| A1 General Principles | Intended performance; safety under intended use conditions; benefit-risk acceptability |
| A2.1 Overview | General design and manufacture requirements |
| A2.2 Clinical Evaluation | Clinical data; intended use; target population; user environment |
| A2.3 Chemical, Physical & Biological | Biocompatibility; chemical composition; physical properties |
| A2.4 Sterility & Biological Contamination | Sterilization validation; sterility assurance level; shelf life |
| A2.5 Environmental & Use Conditions | Performance across storage, transport, and use environment extremes |
| A2.6 Electrical, Mechanical & Thermal Risks | IEC 60601 and ISO 11135 equivalents; mechanical fatigue; thermal protection |
| A2.7 Active Devices | Powered device-specific requirements; connected device interactions |
| A2.8 Software | SaMD lifecycle; cybersecurity; algorithm validation |
| A2.9 Diagnostic & Measuring Devices | Accuracy; repeatability; calibration traceability |
| A2.10 IFU & Labeling | Instructions for use completeness; labeling accuracy |
| A2.11–A2.13 Radiation; Lay Users; Biological Materials | Radiation protection; non-professional user risk; biological origin materials |
| Section 3 & 4 | Device-specific: implants; energy delivery; drug combinations; IVD performance |
The logic of the EP Checklist is a conformity closed loop: the Basic Principles define the requirements → the checklist maps each requirement to a conformity method → the conformity method points to objective evidence in the dossier → the technical reviewer follows this chain to assess whether evidence is complete and sufficient. If all applicable items are addressed with appropriate methods and sufficient evidence, the product passes technical review.
On-Site Technical Review: What NMPA Verifies in Person
For Class III devices and innovative devices, NMPA conducts on-site technical review (现场审评) — sending reviewers to the manufacturer's facility to verify that the registration dossier accurately reflects physical reality. The four review focus areas are:
1. Design and Development Records
Reviewers verify the completeness and integrity of the Design History File (设计开发文件) across all development stages:
- Project planning documentation (立项策划)
- Design inputs and outputs at each development stage
- Design review records
- Verification records (设计验证)
- Validation records (设计确认) including clinical validation management
- Design transfer documentation (设计转换)
- Change management records (设计变更)
A key principle: every stage of design development must be documented with records that allow the complete design evolution — including all changes and the rationale for each — to be traced from initial concept to final product. Gaps in design history are among the most common on-site findings that generate major deficiencies.
2. Raw Materials
Reviewers verify that raw material specifications, qualification records, supplier controls, and incoming inspection procedures match the claims in the dossier — particularly for materials with direct patient contact or functional criticality.
3. Production Management
GMP-compliant production management systems are verified: process validation records, environmental monitoring, equipment calibration, and operator qualification for critical manufacturing steps.
4. Testing and Inspection
In-process and finished product testing records are verified against the test methods and acceptance criteria stated in the product technical requirements (产品技术要求). Test equipment calibration status and laboratory qualification are checked.
Practical Implications: Building Registration-Ready from Day One
The TRL framework and EP Checklist together define what "registration-ready" means in concrete terms. Companies that build these requirements into their development process from the start — rather than retrofitting documentation after technical development is complete — consistently achieve faster, lower-cost registrations:
- Start the EP Checklist at TRL 4. Identifying which Basic Principles apply at the component prototype stage shapes what testing and documentation you build into development — rather than discovering gaps at TRL 8 when dossier assembly begins.
- Design history file discipline from the first prototype. NMPA on-site review checks the entire design history, not just the final design. Retroactively reconstructing records is both unreliable and detectable by experienced reviewers.
- Align clinical study design with EP Chapter A2.2 requirements. Clinical evaluation requirements are defined by the Basic Principles framework — study design should be driven by what A2.2 requires for the specific intended use, not by what was convenient to collect.
- Engage CMDE before committing to clinical trial design. The clinical trial protocol pre-review mechanism now available for innovative devices removes the single most expensive failure mode in the China registration pathway. Use it.
FAQ
No fixed TRL is mandated in regulation, but NMPA's technical review effectively demands TRL 7–8 maturity: a validated engineering prototype that has completed reliability, environmental, and EMC testing in its intended use environment, and that has clinical safety and efficacy data from properly designed studies. Products at TRL 4–5 are not ready for registration and submitting early creates a negative review record without resolving the underlying readiness gaps.
The EP Checklist (医疗器械安全和性能基本原则符合性清单) is China's equivalent of IMDRF 2018 Essential Principles. It is a mandatory submission document mapping each safety and performance requirement to the conformity method and objective evidence provided. Technical review uses it as its primary evaluation index — complete applicable items with sufficient evidence means the product meets essential safety and performance requirements.
Four focus areas: (1) design and development records — complete Design History File across all stages (planning, inputs/outputs, reviews, verification, validation, transfer, changes); (2) raw materials — specifications, supplier controls, incoming inspection; (3) production management — GMP systems, process validation, equipment calibration; (4) in-process and finished product testing — test records vs. product technical requirements, equipment calibration status.
The Valley of Death is the commercialization gap between applied research (TRL 3–5) and a manufacturable, registrable product (TRL 7+). In medical devices, four failure patterns dominate: experiment outputs that are not stable enough to become products; scale-up failure when moving to production volumes; lack of real clinical use scenario validation; and project-dependent R&D that dies when funding ends. Crossing the Valley requires engineering maturity, regulatory documentation discipline, clinical evidence, and quality system compliance simultaneously.
Assessing Your Device's NMPA Registration Readiness?
Our former NMPA specialists conduct TRL-based registration readiness assessments — identifying EP Checklist gaps, design history file deficiencies, and clinical evidence shortfalls before they become dossier failures.
Book a Free Consultation →